Approach to the Patient - Transitions in Osteoporosis Therapy
- 17 November 2025
- journal article
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
- Vol. 111 (2) , e577-e585
Abstract
Moving toward a goal-directed-treatment strategy in osteoporosis necessitates considering the opportunities and challenges associated with transitions in osteoporosis therapy. Some transitions are straightforward; transition from bone anabolic treatment to antiresorptives maintains or further improves the bone mineral density (BMD) increase and the antifracture effect obtained during treatment with a bone anabolic. Transitions from one antiresorptive to another are also, in most cases, safe and may lead to further increases in BMD if the transition is from an oral antiresorptive to a parentally administrated antiresorptive, such as zoledronate or denosumab. However, challenges arise when transitioning from antiresorptives to bone anabolic treatment, as the anabolic effect will be blunted compared to the effect seen in treatment-naïve patients, and transitions involving discontinuation of denosumab after more than 2 to 3 years of treatment. Sequential treatment of osteoporosis is needed for many patients to prevent fractures and obtain BMD levels associated with an acceptable fracture risk. While not all treatment transitions are optimal, the majority are safe, except for transitioning from denosumab to a bone anabolic agent or discontinuation of denosumab without appropriate follow-up treatment. These specific transitions should be avoided.Keywords
This publication has 80 references indexed in Scilit:
- Discontinuation of Denosumab: Gradual Decrease in Doses Preserves Half of the Bone Mineral Density Gain at the Lumbar SpineJBMR Plus, 2023
- Skeletal responses to romosozumab after 12 months of denosumabJBMR Plus, 2021
- Optimizing Sequential and Combined Anabolic and Antiresorptive Osteoporosis TherapyJBMR Plus, 2018
- Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With OsteoporosisJAMA, 2016
- Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchJournal of Bone and Mineral Research, 2015
- The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the HORIZON-Pivotal Fracture Trial (PFT)Journal of Bone and Mineral Research, 2011
- Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: The FLEX TrialJournal of Bone and Mineral Research, 2010
- Effects of Continuing or Stopping Alendronate After 5 Years of TreatmentJAMA, 2006
- Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal OsteoporosisA Randomized Controlled TrialJAMA, 1999
- Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With RaloxifeneResults From a 3-Year Randomized Clinical TrialJAMA, 1999